MB-CART19.1 in refractory SLE

2023-507654-33-00 Protocol M-2022-398 Phase I and Phase II (Integrated) - Other Ongoing, recruiting

Start 12 Aug 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 4 sites · Protocol M-2022-398

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruiting
Participants planned 30
Countries 1
Sites 4

Refractory systemic lupus erythematosus (SLE)

Key facts

Sponsor
Miltenyi Biomedicine GmbH
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20], Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trial duration
12 Aug 2024 → ongoing
Decision date (initial)
2023-10-23
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-507654-33-00
EudraCT number
2022-003137-19

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Refractory systemic lupus erythematosus (SLE)

VersionLevelCodeTermSystem organ class
21.1 PT 10042945 Systemic lupus erythematosus 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Miltenyi Biomedicine GmbH

Sponsor organisation
Miltenyi Biomedicine GmbH
Address
Friedrich-Ebert-Strasse 68, Moitzfeld Moitzfeld
City
Bergisch Gladbach
Postcode
51429
Country
Germany

Scientific contact point

Organisation
Miltenyi Biomedicine GmbH
Contact name
Clinical Trial Desk

Public contact point

Organisation
Miltenyi Biomedicine GmbH
Contact name
Clinical Trial Desk

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 30 4
Rest of world 0

Investigational sites

Germany

4 sites · Ongoing, recruiting
Universitaetsklinikum Wuerzburg AöR
Medizinische Klinik und Poliklinik II, Oberduerrbacher Strasse 6, Grombuehl, Wuerzburg
Otto Von Guericke Universitaet Magdeburg
Zentrum für Innere Medizin Universitätsklinik für Hämatologie und Onkologie, Leipziger Strasse 44, Leipziger Str., Magdeburg
Universitaetsklinikum Tuebingen AöR
Innere Medizin II, Otfried-Mueller-Strasse 10, Nordstadt, Tuebingen
Universitaetsklinikum Erlangen AöR
Medizinische Klinik 3, Ulmenweg 18, Innenstadt, Erlangen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-08-12 2024-10-08

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-10-04 Germany Acceptable
2023-10-17
2023-10-23
2 SUBSTANTIAL MODIFICATION SM-1 2024-04-24 Germany Acceptable
2024-07-02
2024-07-08
3 SUBSTANTIAL MODIFICATION SM-3 2026-02-06 Germany Acceptable
2026-03-24
2026-03-25